» Articles » PMID: 18758088

Effects of Statin Therapy in Children Complicated with Coronary Arterial Abnormality Late After Kawasaki Disease: a Pilot Study

Overview
Journal Circ J
Date 2008 Sep 2
PMID 18758088
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Ongoing low-grade inflammation and endothelial dysfunction persist in patients late after Kawasaki disease (KD). Statins not only reduce cholesterol, but also improve surrogate markers of atherosclerosis and endothelial dysfunction, but their effects for children late after KD complicated with coronary arterial abnormality (CAA) has not been evaluated.

Methods And Results: The 11 KD children complicated with CAA (mean age 12.9+/-2.5 years, mean interval from episode 10.77+/-3.01 years) and 11 age- and gender-matched healthy controls were studied. The KD group received oral simvastatin 10 mg/day for 3 months. Lipid profiles, high-sensitivity C-reactive protein (hs-CRP) and flow-mediated dilation (FMD) of the brachial artery were performed at baseline in both groups and 3 months later in the KD group. At baseline, the KD group had significantly higher hs-CRP level and decreased FMD than the control group. After 3 months' treatment, the KD group showed a significant reduction in the hs-CRP level and a significant increase in FMD.

Conclusions: In this small study, short-term statin therapy appeared to significantly improve chronic vascular inflammation and endothelial dysfunction with no adverse effects in children complicated by CAA late after KD. However, long-term and randomized studies are still needed to make further conclusions.

Citing Articles

Endothelial Dysfunction: Molecular Mechanisms and Therapeutic Strategies in Kawasaki Disease.

Paolini L, Guida F, Calvaruso A, Andreozzi L, Pierantoni L, Lanari M Int J Mol Sci. 2025; 25(24.

PMID: 39769085 PMC: 11676170. DOI: 10.3390/ijms252413322.


Assessment of Endothelial Dysfunction in Patients with Kawasaki Disease: A Meta-Analysis.

Yu X, Wu D, Song G Rev Cardiovasc Med. 2024; 23(8):260.

PMID: 39076622 PMC: 11266953. DOI: 10.31083/j.rcm2308260.


Prevalence of antecedent Kawasaki disease in young adults with suspected acute coronary syndrome in high incidence cohort.

Shyu T, Wu C, Fu Y, Peng Y, Chuang T, Kuo H Front Cardiovasc Med. 2023; 10:1167771.

PMID: 37600029 PMC: 10436480. DOI: 10.3389/fcvm.2023.1167771.


Kawasaki Disease-like Vasculitis Facilitates Atherosclerosis, and Statin Shows a Significant Antiatherosclerosis and Anti-Inflammatory Effect in a Kawasaki Disease Model Mouse.

Motoji Y, Fukazawa R, Matsui R, Nagi-Miura N, Miyagi Y, Itoh Y Biomedicines. 2022; 10(8).

PMID: 35892695 PMC: 9330289. DOI: 10.3390/biomedicines10081794.


Kawasaki Disease: Pathology, Risks, and Management.

Seki M, Minami T Vasc Health Risk Manag. 2022; 18:407-416.

PMID: 35711626 PMC: 9196282. DOI: 10.2147/VHRM.S291762.